Obesity

The Obesity pipeline: 117 tracked drugs, 9 approved for this indication.

9 approved / phase 434 Phase 31 Phase 2/338 Phase 27 Phase 1/224 Phase 14 preclinical / unstaged

Compare the share prices of listed companies in Obesity →

Total attributable cost

$199.1B

$1,861/patient

Drug spend

$21.2B

$198/patient

How this is calculated ↗

BMI >=30 (or >=27 with a weight-related comorbidity) · US

The Obesity pipeline

Key trial results for every approved and late-stage drug: Obesity results by drug.

← all assets